FDA Compounding Pharmacy Regulations for Providers

The Drug Quality and Security Act (DQSA) of 2013 is the primary federal law governing compounding pharmacy regulation. Passed in response to the 2012 NECC meningitis outbreak that killed 64 patients, it created the modern framework providers interact with today.

The DQSA Framework

The DQSA established two distinct regulatory paths for compounding:

• Section 503A: Traditional compounding pharmacies that prepare patient-specific medications under state oversight, with certain FDA exemptions
• Section 503B: Outsourcing facilities that voluntarily register with the FDA and can compound without individual prescriptions under federal cGMP standards

This dual framework means providers must understand which type of pharmacy they're working with, as the rules governing each are fundamentally different.

FDA Oversight of 503A Pharmacies

503A pharmacies are primarily state-regulated, but the FDA retains authority in several areas:

• Cannot compound drugs that are "essentially copies" of commercially available products (with limited exceptions)
• Must compound based on valid patient-specific prescriptions
• Cannot compound drugs that appear on the FDA's "difficult to compound" list
• Cannot use drug substances that fail to meet compendial or FDA-approved standards
• Cannot compound using bulk drug substances not on the FDA's "bulks" list (for non-USP substances)

FDA Oversight of 503B Facilities

• Must register with the FDA voluntarily
• Subject to FDA inspection on the same basis as drug manufacturers
• Must follow cGMP (current Good Manufacturing Practice) standards
• Must report adverse events to the FDA
• Must compound from the FDA's approved bulk substance list
• Can distribute interstate without individual prescriptions

FDA Drug Shortage List and Compounding

The FDA Drug Shortage List plays a critical role in compounding — particularly for high-demand molecules like semaglutide and tirzepatide. When a drug is on the shortage list, compounding pharmacies may have additional flexibility to compound versions of that drug to address patient access gaps.

State vs Federal: Overlapping Authority

Providers should understand that compounding pharmacies operate under both state and federal rules. State pharmacy boards regulate licensing, inspections, and practice standards. The FDA provides the overarching framework. When state and federal rules conflict, the more restrictive standard generally applies.

What This Means for Providers

When selecting a compounding pharmacy partner, verify:

• State licensure and good standing with state pharmacy boards
• USP compliance (795, 797, 800) for 503A pharmacies
• FDA registration status for 503B facilities
• Third-party testing beyond minimum requirements
• Transparently shared Certificates of Analysis